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Summary
 
Mobilization of bone marrow eosinophils is a critical early step in their trafficking to the lung
during allergic inflammatory reactions. We have shown previously that the cytokine interleu-
kin (IL)-5, generated during an allergic inflammatory reaction in the guinea pig, acts systemi-
cally to mobilize eosinophils from the bone marrow. Here, we have investigated the mecha-
nisms underlying this release process. Examination by light and electron microscopy revealed
the rapid migration of eosinophils from the hematopoietic compartment and across the bone
marrow sinus endothelium in response to IL-5. Using an in situ perfusion system of the guinea
pig hind limb, we showed that IL-5 stimulated a dose-dependent selective release of eosino-
phils from the bone marrow. Eosinophils released from the bone marrow in response to IL-5
expressed increased levels of 
 
b
 
2
 
 integrin and a decrease in L-selectin, but no change in 
 
a
 
4
 
 inte-
grin levels. A 
 
b
 
2
 
 integrin–blocking antibody markedly inhibited the mobilization of eosinophils
from the bone marrow stimulated by IL-5. In contrast, an 
 
a
 
4
 
 integrin blocking antibody in-
creased the rate of eosinophil mobilization induced by IL-5. In vitro we demonstrated that IL-5
stimulates the selective chemokinesis of bone marrow eosinophils, a process markedly inhibited
by two structurally distinct inhibitors of phosphatidylinositol 3-kinase, wortmannin and
LY294002. Wortmannin was also shown to block eosinophil release induced by IL-5 in the
perfused bone marrow system. The parallel observations on the bone marrow eosinophil re-
lease process and responses in isolated eosinophils in vitro suggest that eosinophil chemokinesis
is the driving force for release in vivo and that this release process is regulated by 
 
a
 
4
 
 and 
 
b
 
2 
 
in-
tegrins acting in opposite directions.
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T
 
he cytokine IL-5 regulates the development and func-
tion of eosinophils. In the bone marrow, IL-5 stimu-
lates the expansion of eosinophil precursors (1) and is a late
differentiation factor for eosinophils (2, 3). As a conse-
quence, IL-5 transgenic mice exhibit a marked blood and
tissue eosinophilia (4). IL-5 also regulates certain functions
of mature eosinophils. In particular, IL-5 has the ability to
prime eosinophils, increasing their responsiveness to medi-
ators that stimulate degranulation (5), the respiratory burst,
and chemotaxis (6, 7). Finally, IL-5 is an important survival
factor for eosinophils because it inhibits their apoptosis (8).
IL-5 mRNA is upregulated in tissues, including the air-
ways (9, 10), skin (11), intestinal mucosa (12), bladder (13),
and heart (14), during eosinophilic inflammatory reactions.
IL-5 protein has been detected in the bronchoalveolar la-
vage fluid of allergen-challenged sensitized mice (15) and in
the blood of asthmatics (16). In animal models of allergic
inflammation, recruitment of eosinophils into the lungs and
airway hyperreactivity is suppressed by neutralizing Abs to
IL-5 (17, 18). Similarly, IL-5 gene disruption abolishes
eosinophilia, airway hyperreactivity, and lung damage in a
mouse model of asthma (19). These observations support
the concept that IL-5 is an important endogenous eosino-
phil chemoattractant (20).
Aerosolized allergen challenge of sensitized guinea pigs
results in a recruitment of eosinophils into the lung tissue.
We showed that bronchoalveolar lavage fluid from these
guinea pigs contained an eosinophil chemoattractant activity
that did not correspond to IL-5, and sequencing revealed
eotaxin, a novel CC chemokine (21–23). The kinetics of
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eotaxin generation correlated with the recruitment of eo-
sinophils into the lung tissue (24). However, recruitment,
but not eotaxin generation, was inhibited by pretreatment
of guinea pigs with the anti–IL-5 mAb TRFK-5 (24).
Thus, it appears that in this model IL-5 plays an important
role in eosinophil recruitment, but not as a significant
chemoattractant.
We demonstrated that intravenous administration of
IL-5 into guinea pigs resulted in a rapid blood eosinophilia
due to the mobilization of eosinophils from a storage pool
in the bone marrow (25). Significantly, intradermally in-
jected IL-5 did not induce eosinophil recruitment (25).
This blood eosinophilia had a marked potentiating effect
on the numbers of eosinophils recruited to the sites of in-
tradermally injected eotaxin. Thus, IL-5 and eotaxin act
cooperatively, with IL-5 mobilizing eosinophils from the
bone marrow and eotaxin recruiting eosinophils locally
(25). Similar cooperative effects of eotaxin and IL-5 have
been shown in the mouse (26). Indeed, intradermal admin-
istration of eotaxin did not induce eosinophil accumulation
in IL-5–deficient mice, and in one study eotaxin-stimu-
lated eosinophil accumulation in the lungs was only consis-
tently observed in IL-5 transgenic mice that have a pro-
nounced basal blood eosinophilia (26). We subsequently
showed that when sensitized guinea pigs were challenged
with aerosolized allergen, eosinophils were mobilized from
the bone marrow into the blood and subsequently accumu-
lated in the lung (24). Bone marrow eosinophil release,
blood eosinophilia, and lung eosinophilia were abrogated
by pretreatment of guinea pigs with anti–IL-5 mAb (24).
Our studies suggest that IL-5 plays a central role in the mo-
bilization of eosinophils from the bone marrow, an impor-
tant early step in eosinophil trafficking during the allergic
inflammatory response.
The molecular mechanisms regulating the release of
eosinophils from the bone marrow are poorly understood.
Egress from the bone marrow may involve downregulation
of specific adhesive interactions, increased motility, migra-
tion through the hematopoietic compartment, and trans-
migration across the sinus endothelium. This paper explores
the mechanisms underlying mobilization of eosinophils from
the bone marrow induced by IL-5.
 
Materials and Methods
 
Animals.
 
Male Dunkin Hartley guinea pigs (250–350 g) were
obtained from Harlan Olac, Ltd. (Bicester, Oxfordshire, UK).
 
Materials.
 
Human recombinant IL-5 was a gift from Dr.
T.N.C. Wells, (Serona Pharmaceutical Research Institute, Geneva,
Switzerland). Anti-
 
a
 
4
 
 integrin chain (CD49d) mAb (HP1/2) and
nonbinding isotype-matched control mAb (1e6) were gifts from
Dr. R. Lobb (Biogen Inc., Boston, MA). Anti-
 
b
 
2
 
 integrin chain
(CD18) mAb (6.5E) was a gift from Dr. M. Robinson (Celltech
Therapeutics, Ltd., Slough, UK). 6.5E F(ab
 
9
 
)
 
2
 
 fragments were
produced from the whole IgG
 
1
 
 Ab by D. King (Celltech Thera-
peutics, Ltd.) using bromelain digestion. Isotype-matched control
F(ab
 
9
 
)
 
2
 
 fragments [ENA2 F(ab
 
9
 
)
 
2
 
] were also a gift from Dr. M.
Robinson. Anti-L-selectin (CD62L) mAb (MEL-14) was pur-
chased from Serotec Ltd. (Kidlington, Oxford, UK). HBSS with
and without Ca
 
2
 
1
 
/Mg
 
2
 
1
 
 and Hepes was purchased from Life
Technologies (Paisley, UK). Hypnorm (fentanyl citrate 0.315
mg/ml, fluanisone 10 mg/ml) was purchased from Janssen Phar-
maceuticals, Ltd. (Oxford, UK). Hypnovel (Midazolam, 5 mg/
ml) was purchased from Roche (Welwyn, UK). Expiral (sodium
pentobarbitone 200 mg/ml) was purchased from May and Baker
(Dagenham, UK). EasyLyse erythrocyte lysis kits were purchased
from Universal Biologicals (London, UK). Methylene blue,
eosin, May-Grunwald, and Giemsa stains were purchased from
Merck (Dagenham, UK). Transwell inserts with 3-
 
m
 
m pores
were purchased from Millipore (Watford, UK). Kimura’s stain for
positive identification of eosinophils was prepared as previously
described (27). Wortmannin, LY294002, rapamycin, and all other
reagents were purchased from Sigma Chemical Co. (Poole, UK).
Modified Krebs-Ringer bicarbonate buffer of the following
composition was used in perfusion experiments: 10 mM 
 
d
 
-Glu-
cose, 2.50 mM CaCl
 
2
 
, 0.49 mM MgCl
 
2 
 
· 6H
 
2
 
O, 4.56 mM KCl,
120 mM NaCl, 0.7 mM Na
 
2
 
HPO
 
4
 
, 1.5 mM NaH
 
2
 
PO
 
4
 
, and 24
mM NaHCO
 
3
 
, supplemented with Ficoll T-70 4% and BSA
0.1% and gassed with 95% O
 
2
 
, 5% CO
 
2
 
.
 
Measurement of Intrasinus Eosinophils by Light Microscopy.
 
Guinea pigs were sedated with Hypnorm (0.2 ml i.m.) and in-
jected intravenously with IL-5 (30 pmol/kg) or vehicle (PBS/
0.1% very low endotoxin BSA). After 30 min, the guinea pigs
were killed with Expiral (250 mg/kg by cardiac puncture) and
the femurs were removed quickly. The ends of the femur were
removed and femoral marrow was removed from the femoral
shaft very gently using an applicator stick so as to not disrupt the
cytoarchitecture of the marrow. The femoral marrow was fixed
immediately in a 3.7% paraformaldehyde solution for 2 h. The
tissue was then dehydrated in an ethanol series (30–100%) before
being embedded in JB-4 resin as per the manufacturer’s instruc-
tions (Polysciences, Warrington, UK). 3-
 
m
 
m sections were cut
using a Reichart microtome and stained with May-Grunwald and
Giemsa to visualize eosinophils. More than 500 intrasinus leuko-
cytes were counted per section of femoral marrow and classified
as eosinophils or other leukocytes based on positive or negative
staining, respectively, with May-Grunwald (
 
n
 
 5 
 
3 sections/mar-
row, 7–10 animals).
 
Transwell Migration Assay.
 
Guinea pigs were killed with Ex-
piral and the femurs were removed quickly. The femoral shaft
was flushed with 5 ml of cell buffer (HBSS without Ca
 
2
 
1
 
/Mg
 
2
 
1
 
containing 30 mM Hepes and 0.25% BSA, pH 7.4) containing 10
U/ml of heparin. Displaced cells were gently resuspended and
centrifuged (200 
 
g
 
 for 7 min at 20
 
8
 
C), and the cell pellet was re-
suspended in 1 ml of cell buffer. Erythrocytes were removed us-
ing hypotonic shock lysis (addition of 10 ml 0.2% NaCl followed
by 10 ml of 1.6% NaCl to restore isotonicity). After centrifuga-
tion (200 
 
g
 
 for 7 min at 20
 
8
 
C), the leukocyte pellet was resus-
pended in assay buffer (HBSS with Ca
 
2
 
1
 
/Mg
 
2
 
1
 
 containing 30
mM Hepes and 0.25% BSA, pH 7.4). Bone marrow leukocytes
(3 
 
3 
 
10
 
6
 
 cells in 0.2 ml assay buffer) were placed in the upper
chamber of Transwell filters (3-
 
m
 
m pore diameter) that were in
turn placed in individual wells of a 24-well cell culture plate con-
taining 0.3 ml of assay buffer. To demonstrate chemokinesis of
guinea pig bone marrow eosinophils, IL-5 (0–3 nM) was placed
in the upper and lower chambers in a checkerboard pattern. In
some experiments bone marrow leukocytes were incubated with
wortmannin, LY294002, or rapamycin for 30 min at 37
 
8
 
C before
being placed in the upper Transwell chamber. Chambers were
incubated for 60 min at 37
 
8
 
C. Cells that migrated into the bot-
tom chamber after 60 min were counted using a flow cytometer
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(FACScan
 
Ò
 
, Becton Dickinson, San Jose, CA), with relative cell
counts obtained by acquiring events for a set time period of 60 s.
This counting method was highly reproducible and enabled gat-
ing on the different leukocyte populations and the exclusion of
debris. Counts obtained in this way closely matched those ob-
tained by light microscopy.
 
In Situ Perfusion of the Guinea Pig Hind Limb.
 
The guinea pig
hind limb was perfused as previously described in detail (28).
Guinea pigs were anesthetized and the external iliac artery and
vein were exposed. The following arteries and their satellite veins
were ligated with 5/0 braided silk suture: caudal abdominal ar-
tery, superficial iliac circumflex artery, and pudendoepigastric
trunk. The animals were killed with Expiral (250 mg/kg by car-
diac puncture). Cannulas polyethylene (0.8 mm outside diameter;
Portex, London, UK) were immediately inserted into the exter-
nal iliac artery and vein and pushed down under the inguinal lig-
ament into the femoral artery and vein. Cannulas were tied in
with 5/0 braided silk suture. Modified Krebs-Ringer bicarbonate
buffer (37
 
8
 
C, gassed with 95% O
 
2
 
, 5% CO
 
2
 
; composition detailed
above) was infused (3.4 ml/min) via the arterial cannula and re-
moved from the venous cannula using a Minipuls peristaltic
pump (Anachem, Luton, UK). Perfusate fractions were collected
every 10 min and centrifuged (300 
 
g
 
 for 10 min at 20
 
8
 
C), and the
cell pellet was resuspended in Kimura’s stain. Nucleated leuko-
cytes and Kimura-positive eosinophils were counted in an Im-
proved Neubauer Hemacytometer. In some experiments, cyto-
centrifuge preparations of leukocytes in each fraction were
stained with methylene blue and eosin to perform a differential
leukocyte count.
 
Measurement of Eosinophil Surface Adhesion Molecule Expression.
 
The guinea pig hind limb was set up for in situ perfusion as de-
scribed above, and IL-5 was infused (0.4 nM) for 120 min. The
leukocytes released were collected onto ice and immediately cen-
trifuged (300 
 
g
 
 for 10 min at 4
 
8
 
C), and the cell pellet was resus-
pended at 10
 
6
 
 leukocytes/ml in labeling buffer (ice-cold HBSS
without Ca
 
2
 
1
 
/Mg
 
2
 
1
 
 containing 30 mM Hepes and 0.25% BSA,
pH 7.4). A control population of leukocytes from nonperfused
femoral bone marrow was prepared as directed for the Transwell
filter migration assay described in detail above. Bone marrow leu-
kocytes were resuspended as a single cell population at 10
 
6
 
 leuko-
cytes/ml in labeling buffer and were incubated with mAb against
L-selectin (MEL-14, 300 
 
m
 
g/ml), 
 
b
 
2
 
 integrin (6.5E, 10 
 
m
 
g/ml),
 
a
 
4
 
 integrin (HP1/2, 10 
 
m
 
g/ml), or isotype-matched control Ab
for 30 min on ice. MEL-14, 6.5E and HP1/2 have been shown
to cross-react with their respective guinea pig antigens (29, 30).
Leukocytes were washed twice in labeling buffer and incubated
with FITC-conjugated secondary Ab [1:20 dilution of F(ab
 
9
 
)
 
2
 
goat anti–murine IgG-FITC or goat anti–rat IgG-FITC; DAKO,
High Wycombe, Buckinghamshire, UK] for 30 min on ice. Leu-
kocytes were washed twice in labeling buffer and resuspended in
FACS
 
Ò
 
 flow for analysis using a FACScan
 
Ò
 
 flow cytometer. Bone
marrow eosinophils were gated by the characteristic forward/side
scatter profile of these leukocytes, as previously described (28).
 
Transmission Electron Microscopy.
 
The guinea pig hind limb was
set up for in situ perfusion as described above. IL-5 was infused
(0.8 nM) for 60 min, at which point the hind limb was perfused-
fixed with 2.5% gluteraldehyde buffered with sodium cacodylate.
The femur was removed and placed in fresh cacodylate-buffered
2.5% gluteraldehyde fixative for 12 h. The femur was then sawn
in half and the fixed marrow was carefully pushed out with an ap-
plicator stick. The marrow was rinsed with 0.1 M cacodylate
buffer, postfixed in 2% OsO
 
4
 
 buffered with 0.1 M sodium cac-
odylate, and then dehydrated through an ethanol series (30–
100%). During dehydration, the marrow was stained en bloc with
a saturated solution of uranyl acetate in 50% ethanol. Marrow
samples were embedded in Araldite (Ciba Chemical Co.), and ul-
trathin sections were prepared using a Reichart ultramicrotome.
Ultrathin sections were placed on 200-mesh copper grids and fur-
ther stained with uranyl acetate and lead citrate. Sections were
examined and photographed in a Philips EM 301 transmission
electron microscope. Correlative light microscopy was carried
out using semithin sections stained with toluidine blue.
 
Eosinophil Accumulation in the Femoral Bone Marrow.
 
Guinea pig
peritoneal eosinophils were prepared to 
 
.
 
95% purity and labeled
with 
 
111
 
In as previously described in detail (31). Before injection
into recipient guinea pigs, 
 
111
 
In-labeled eosinophils were pre-
treated with the anti-
 
a
 
4
 
 (HP1/2, 10 
 
m
 
g/ml) or isotype-matched
control mAb (1e6, 10 
 
m
 
g/ml) for 20 min at 37
 
8
 
C. Recipient
guinea pigs were sedated (Hypnorm, 0.2 ml i.m.) and injected
with 
 
111
 
In-labeled eosinophils (10
 
6
 
 eosinophils/kg) via the mar-
ginal ear vein. After 1 h, the animals were killed and both femurs
were removed, cleaned of connective tissue and muscle, and
weighed. The number of 
 
111
 
In-labeled eosinophils accumulated
in each femur was measured using an automatic gamma counter
(Canberra Packard, Pangbourne, UK) as previously described (31).
 
Statistical Analysis.
 
For analysis of two groups, the unpaired
two-way Student’s 
 
t
 
 test was used. For analysis of three or more
groups, one-way analysis of variance followed by either Bonfer-
roni’s multiple comparisons test or Dunnett’s test for comparison
with a control group was used.
 
 P 
 
, 
 
0.05 was considered signifi-
cant. All data are expressed as arithmetic mean 
 
6
 
 SEM for
 
 n 
 
ob-
servations.
 
Results
 
IL-5 Stimulates a Rapid Migration of Eosinophils from the
Hematopoietic Compartment into the Venous Sinusoids.
 
Eosin-
ophils mobilized from the bone marrow may originate
from either the extravascular hematopoietic compartment
or a marginating intravascular pool within the bone mar-
row sinuses. To distinguish between these two possibilities,
femoral bone marrow was removed from guinea pigs 30
min after intravenous injection of IL-5 (30 pmol/kg) or
PBS, and the location of the eosinophils within the bone
marrow was determined by light microscopy. In the PBS-
injected guinea pigs, very few intrasinus eosinophils were
evident, suggesting that there was not a significant margin-
ating intravascular pool of eosinophils (Fig. 1). The number
of eosinophils present in the venous sinusoids, expressed as
a percentage of the total number of leukocytes in the
Figure 1. Rapid elevation of intrasinus eosin-
ophil numbers after intravenous IL-5. Guinea
pigs were injected with IL-5 (30 pmol/kg) or
vehicle (PBS/0.1% BSA). The femoral bone
marrow was removed after 30 min for histolog-
ical analysis of intrasinus eosinophil levels. Data
expressed as the percentage of eosinophilic in-
trasinus leukocytes, mean 6 SEM (n 5 7–10
animals).
 1624
 
Acute Bone Marrow Eosinophil Mobilization Stimulated by IL-5
 
venous sinusoids, increased fivefold 30 min after intrave-
nous IL-5 injection (Fig. 1). There was no significant in-
crease in peripheral blood eosinophil numbers at this time
point (data not shown). These results demonstrate that mo-
bilization involves the migration of eosinophils from the
hematopoietic compartment into the bone marrow sinuses.
 
Transmission Electron Microscopy Demonstrates Possible Stages
of Eosinophil Mobilization from the Bone Marrow.
 
To exam-
ine this release process in more detail, we perfused the
guinea pig hind limb with IL-5 (0.8 nM) for 60 min and
then rapidly perfused-fixed it. Ultrathin sections of the
bone marrow were stained with lead citrate and uranyl ace-
tate, and examined by transmission electron microscopy.
Eosinophils, readily identified by their characteristic sec-
ondary cytoplasmic granules, could be seen at different
stages of emigration as shown in the electron micrographs.
Fig. 2 
 
a
 
 shows an eosinophil located within the hematopoi-
etic compartment, abutting a thin fenestrated region of the
Figure 2. Transmission electron microscopy illustrating egress of eosinophils from the femoral bone marrow. Guinea pig hind limb was infused with
IL-5 (0.8 nM) for 60 min and perfused fixed, and ultrathin sections were prepared for observation by transmission electron microscopy. Original magni-
fication: A, 318,600; B, 39,400; C, 37,300; D, 36,900.
1625 Palframan et al.
sinusoidal endothelium. Fig. 2 b shows an eosinophil in the
process of transmigration through the sinusoidal endothe-
lium, apparently not through the endothelial cell junctions.
There is marked deformation of the eosinophil as it
traverses the endothelium, consistent with passage through
a tight fitting migration pore. Fig. 2 c shows an eosinophil
within the sinus lumen, attached to the luminal surface of
the sinusoidal endothelium. Fig. 2 d shows an eosinophil
within the sinus lumen, apparently not attached to the sinus
endothelium. Although these transmission electron micro-
graphs are static images, when assembled in this sequence
they permit reconstruction of the probable stages by which
eosinophils emigrate from the bone marrow.
IL-5 Stimulates Mobilization of Eosinophils from the Guinea
Pig Hind Limb. To investigate directly the kinetics and
molecular mechanisms of eosinophil release from bone
marrow, we used the in situ hind limb perfusion system in
the guinea pig. During perfusion with PBS there was a
steady release of leukocytes from the perfused hind limb
(1.04 3 107 6 1.24 3 106 in 2 h). Differential leukocyte
counts from cytospin preparations showed that these leu-
kocytes were predominantly neutrophils (.90%) both of
the mature, segmented band form (z80%) and the less ma-
ture, unsegmented band form (z20%). Very few eosino-
phils were released under basal conditions (0.5 3 106 6 0.1 3
106 in 2 h) (Fig. 3 a). In contrast, infusion with IL-5 (0.1–
0.8 nM, indicated by the solid bar) stimulated a dose-
dependent release of eosinophils (Fig. 3 a). IL-5–stimulated
release of eosinophils was rapid, with a maximum rate of
release attained after 1 h of IL-5 infusion (Fig. 3 a). The
rate of eosinophil release did not change significantly be-
tween 1 and 2 h when IL-5 was infused at a concentration
of 0.1 and 0.4 nM. When IL-5 was infused at 0.8 nM, the
rate of eosinophil release attained at 1 h was higher than for
the lower concentration of IL-5 but reduced at later time
points. This may reflect depletion of a finite pool of mobi-
lizable eosinophils. Cytospin preparations showed that the
eosinophils released by IL-5 had a bilobed nucleus, charac-
teristic of terminally differentiated eosinophils (data not
shown). The total number of noneosinophilic leukocytes
released was unaffected by infusion with IL-5 (Fig. 3 b).
Surface Adhesion Molecule Expression on Eosinophils Released
from the Femoral Bone Marrow. The in situ hind limb per-
fusion system was used to determine whether there was a
change in the expression of adhesion molecules on eosin-
ophils mobilized in response to IL-5. IL-5 (0.4 nM) was
infused into the hind limb for 120 min and the leukocytes
released were collected on ice. Leukocytes from a nonper-
fused bone marrow were collected and prepared as de-
scribed in Materials and Methods to provide the control
population and kept on ice as above. The leukocytes were
labeled with mAbs raised against L-selectin and b2 and a4
integrins, and binding was analyzed by flow cytometry.
Figure 3. IL-5–stimulated mo-
bilization of eosinophils from the
femoral bone marrow measured
using the in situ perfused hind
limb preparation. (A) Kinetics of
eosinophil release stimulated by a
120-min infusion (solid bar) of
IL-5 (0.1–0.8 nM) or vehicle
(PBS/0.1% BSA). Results ex-
pressed as the number of eosino-
phils per milliliter of perfusate in
each 10-min fraction, mean 6
SEM (n 5 5 perfusions). (B) To-
tal eosinophil and total other
leukocyte release induced by a
120-min infusion of IL-5 (0.1–
0.8 nM) or vehicle. Results are
expressed as the total number of
eosinophils or total number of
other leukocytes released during
the 120-min infusion period,
mean 6 SEM (n 5 5 perfusions).
*P , 0.05, **P , 0.01.
Figure 4. Changes in surface adhesion molecule expression on eosin-
ophils mobilized from the bone marrow by IL-5. Binding of mAb recog-
nizing L-selectin (A), b2 integrin (B), or a4 integrin (C), to eosinophils
mobilized from perfused femoral marrow by IL-5 (0.4 nM, 120-min infu-
sion) was analyzed by indirect immunofluorescence flow cytometry. Bind-
ing to eosinophils mobilized from the bone marrow is shown by the solid
histograms, binding to control bone marrow eosinophils is shown by the
open histograms. Binding of isotype matched control Ab is shown by the
dotted line. Each histogram is representative of three separate experiments.
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Fig. 4 shows binding of mAb against L-selectin (Fig. 4 a),
b2 integrin (Fig. 4 b), or a4 integrin (Fig. 4 c) to eosinophils
released from the perfused hind limb in response to IL-5
(0.4 nM, 120-min infusion, filled histograms) or eosinophils
from control, nonperfused guinea pig bone marrow (open
histograms). The binding of control Ab to eosinophils from
control, nonperfused, guinea pig bone marrow is shown by
the dotted line histogram. As shown in Fig. 4 a there is no
detectable expression of L-selectin on eosinophils mobi-
lized in response to IL-5 as compared with control bone
marrow eosinophils (Fig. 4 a), suggesting that L-selectin
shedding is associated with eosinophil mobilization. Con-
versely, eosinophils mobilized by IL-5 were shown to ex-
press increased levels of the b2 integrin when compared
with control bone marrow eosinophils (99% increase) (Fig.
4 b). There was no significant difference in the expression
of the a4 integrin between IL-5–mobilized eosinophils and
control bone marrow eosinophils (Fig. 4 c).
The Effect of an Anti-b2 mAb on IL-5–stimulated Eosinophil
Mobilization from Femoral Bone Marrow. Perfusion of the
femoral bone marrow in situ with IL-5 (0.4 nM) or PBS in
the presence of either the b2-blocking mAb 6.5E (10 mg/
ml) or an isotype-matched control mAb (10 mg/ml) was
performed to investigate the role of the b2 integrin in the
IL-5–stimulated mobilization of eosinophils. Infusion of
6.5E markedly reduced the rate of IL-5–stimulated eosino-
phil release from the perfused hind limb, reducing the total
number of eosinophils released in response to IL-5 by 40%
over the 2-h perfusion period (Fig. 5). As noted above,
there is a basal release of leukocytes other than eosinophils
(comprising .90% neutrophils) that is not affected by the
infusion of IL-5. However, the release of these noneosino-
philic leukocytes from the perfused hind limb was signifi-
cantly reduced by the infusion of 6.5E (IL-5 plus control
mAb released 9.0 6 0.55 3 106 noneosinophilic leuko-
cytes; IL-5 plus 6.5E released 5.1 6 0.9 3 106 noneosino-
philic leukocytes, P , 0.01 for n 5 5 experiments). To ex-
clude the possibility of Fc receptor cross-linking, we
manufactured anti-b2 F(ab9)2 fragments and investigated
whether these would have the same effect on leukocyte re-
lease as the whole (IgG1) Ab. Indeed, anti-b2 F(ab9)2 (10
mg/ml) inhibited noneosinophil leukocyte release by 31%
and IL-5–stimulated eosinophil release by 29% (data not
shown). These results suggest that both basal leukocyte re-
lease and IL-5–stimulated mobilization of eosinophils from
the bone marrow is dependent on the b2 integrin.
The Effect of an Anti-a4 mAb on IL-5–stimulated Eosinophil
Mobilization from the Bone Marrow. Perfusion of the femo-
ral bone marrow in situ with IL-5 (0.4 nM) or PBS in the
presence of either the a4-blocking mAb, HP1/2 (10 mg/
ml) or an isotype-matched control mAb (10 mg/ml) was
performed to investigate the role of the a4 integrin in the
IL-5–stimulated mobilization of eosinophils. Basal release
of eosinophils and noneosinophilic leukocytes in the PBS-
infused group was not altered by infusion of anti-a4 mAb
(Fig. 6 a and data not shown). However, infusion of anti-
a4 mAb together with IL-5 (0.4 nM) resulted in a signifi-
cantly increased initial rate of eosinophil release when
compared with IL-5 infused together with the control
mAb (Fig. 6 a). At later time points, the rate of eosinophil
release in the presence of IL-5 and anti-a4 mAb was re-
duced to control levels. This reduced rate of release is simi-
lar to that seen in Fig. 3 (0.8 nM IL-5) and may reflect de-
pletion of the mobilizable pool of eosinophils. The total
number of eosinophils mobilized by IL-5 was increased by
40% in the presence of the anti-a4 mAb (Fig. 6 a).
The Effect of an Anti-a4 mAb on IL-5–stimulated Blood
Eosinophilia In Vivo. The effect of the anti-a4 mAb HP
1/2 on IL-5–stimulated blood eosinophilia was examined
in guinea pigs in vivo. Guinea pigs were coinjected intra-
venously with anti-a4 mAb or an isotype-matched control
mAb together with either IL-5 or PBS. Peripheral blood
samples were collected before and 5, 10, 15, 30, and 60
min after the intravenous injection, and the numbers of cir-
culating eosinophils were determined. Intravenous injec-
tion of PBS together with either the control mAb or anti-
a4 mAb had no effect on the basal number of circulating
eosinophils at any time point. Intravenous injection of IL-5
(30 pmol/kg) stimulated an increase in the number of cir-
culating eosinophils, reaching an 11-fold elevation by 60
min. The anti-a4 mAb accelerated the blood eosinophilia
response, such that a significant increase in circulating eo-
sinophils was observed first at 30 min compared with 60
min in the absence of mAb (Fig. 6 b). Anti-a4 mAb had no
significant effect on blood eosinophil levels measured 60
min after IL-5 injection.
Figure 5. Effect of anti-b2 integrin mAb on IL-5–stimulated eosinophil
mobilization from the perfused hind limb. (A) Kinetics of eosinophil mo-
bilization are shown on the left hand axis. The hind limb was infused with
IL-5 (0.4 nM) together with anti-b2 mAb (10 mg/ml, filled squares) or iso-
type-matched control mAb (10 mg/ml, filled circles). Infusion of PBS vehi-
cle together with anti-b2 integrin mAb and isotype-matched control mAb
are shown by open squares and open circles, respectively. Data expressed
as the number of eosinophils per milliliter of perfusate in each 10-min
fraction, mean 6 SEM (n 5 4 separate perfusions). Total eosinophil mo-
bilization induced by a 120-min infusion of IL-5 (0.4 nM) or vehicle in
the presence of anti-b2 integrin mAb (10 mg/ml) or isotype-matched
control mAb (10 mg/ml) is shown on the right hand axis. Results are ex-
pressed as the total number of eosinophils mobilized during the 120-min
infusion period, mean 6 SEM (n 5 4). *P , 0.05.
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The Effect of an Anti-a4 mAb on the Accumulation of Eosino-
phils in the Bone Marrow. Vascular cell adhesion molecule
(VCAM)-11 is expressed constitutively on the sinus endo-
thelium (32). One possible explanation for the above re-
sults is that there is a tendency for eosinophils that have mi-
grated through the sinus endothelium to be retained on the
luminal surface (as seen in Fig. 2 c), using a4 integrins for
attachment. To address this possibility, we used 111In-labeled
guinea pig peritoneal eosinophils as a surrogate for the
newly migrated cells. Fig. 6 d shows that a significant pro-
portion of these intravenously-injected cells localized in the
bone marrow and that preincubation of these cells with
anti-a4 mAb significantly reduced this effect.
IL-5–stimulated Chemokinesis of Guinea Pig Femoral Bone
Marrow Eosinophils. Using a Transwell filter assay, we in-
vestigated whether IL-5 could stimulate the selective mi-
gration of guinea pig bone marrow eosinophils in vitro. A
mixed population of guinea pig bone marrow leukocytes
was placed into the upper Transwell chamber. IL-5 (0.03–1
nM) was added to the upper and/or lower chambers of the
Transwell system in a checkerboard analysis, and after 90
min the number of eosinophils migrated into the lower
chamber was quantified by flow cytometry. The results in
Table 1 show that IL-5 stimulated a dose-dependent mi-
gration of eosinophils from the upper chamber into the
lower chamber. The migration was not dependent on a
positive gradient of IL-5. These results demonstrate that
IL-5 is chemokinetic and not chemotactic for guinea pig
bone marrow eosinophils. IL-5 stimulated a significant in-
crease in the migration of eosinophils at 30 pM with a
maximal effect at 1 nM. IL-5 did not stimulate the migra-
tion of any other type of leukocyte, consistent with the se-
lective mobilization of eosinophils by IL-5 in the in situ
perfusion system and in vivo.
The Effect of Wortmannin, LY294002, and Rapamycin on
IL-5–stimulated Chemokinesis of Bone Marrow Eosinophils.
Using the Transwell filter assay, we examined the role of
phosphatidylinositol (PI) 3-kinase in IL-5–stimulated bone
marrow eosinophil chemokinesis. This was investigated us-
ing two specific inhibitors of PI 3-kinase, wortmannin and
LY294002, which are structurally unrelated compounds
that inhibit by different mechanisms (33–35). Femoral mar-
row leukocytes were incubated with wortmannin (1–50
nM) or LY294002 (1–20 mM) for 30 min at 378C before
being added to the upper Transwell chamber in the pres-
ence of IL-5 (3 nM). Eosinophils that accumulated in the
lower chamber were quantified by flow cytometry after 1 h.
Both wortmannin (25 and 50 nM) and LY294002 (1–20
mM) significantly inhibited IL-5–induced chemokinesis of
guinea pig femoral marrow eosinophils (Fig. 7 a). These re-
sults indicate that IL-5–stimulated chemokinesis of guinea
pig bone marrow eosinophils involves signaling through
the PI 3-kinase pathway.
Figure 6. Effect of anti-a4 integrin mAb on (A) IL-5–stimulated eosin-
ophil mobilization from the perfused femoral bone marrow, (B) IL-5–
stimulated blood eosinophilia in vivo, and (C) eosinophil accumulation in
the femur. (A) Kinetics of eosinophil mobilization from the perfused hind
limb stimulated by IL-5 (0.4 nM) in the presence of anti-a4 integrin mAb
(10 mg/ml, filled squares) or isotype-matched control mAb (10 mg/ml,
filled circles) is shown on the left hand axis. Eosinophil mobilization stimu-
lated by PBS vehicle in the presence of isotype-matched control mAb and
anti-a4 integrin mAb are shown by open circles and squares, respectively.
Data expressed as the number of eosinophils per milliliter of perfusate in
each 10-min fraction, mean 6 SEM (n 5 5–6 separate perfusions). Total
eosinophil mobilization induced by a 120-min infusion of IL-5 (0.4 nM)
or vehicle in the presence of anti-a4 integrin mAb (10 mg/ml) or isotype-
matched control mAb (10 mg/ml) is shown on the right hand axis.
Results are expressed as the total number of eosinophils mobilized during
the 120-min infusion period, mean 6 SEM (n 5 6). *P , 0.05. (B) Pe-
ripheral blood eosinophilia stimulated by IL-5 (30 pmol/kg i.v.) co-
injected with either anti-a4 integrin mAb (4 mg/kg i.v., filled squares) or
isotype-matched control mAb (4 mg/kg i.v., filled circles). Blood eosino-
phil levels in PBS injected animals in the presence of anti-a4 integrin
mAb or isotype-matched control mAb is shown by open squares and cir-
cles, respectively. Data expressed as number of eosinophils per milliliter of
blood, mean 6 SEM (n 5 4). *P , 0.05. (C) Accumulation of 111In-
labeled peritoneal eosinophils in the guinea pig femur. 111In-labeled eosin-
ophils were pretreated in vitro with either anti-a4 integrin mAb (10 mg/
ml) or isotype-matched control mAb (10 mg/ml) before intravenous
injection into recipient guinea pigs. After 2 h, femoral 111In-eosinophil
accumulation was measured using a gamma counter. Data are expressed
as the number of eosinophils per gram of femur, mean 6 SEM (n 5 5).
*P , 0.05.
1Abbreviations used in this paper: PI 3-kinase, phosphatidylinositol 3-kinase;
p70S6K, p70 S6-kinase; VCAM-1, vascular cell adhesion molecule 1;
VLA4, very late antigen 4.
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One of the downstream targets for PI 3-kinase is the
serine/threonine kinase p70 S6-kinase (p70S6K). We ex-
amined whether this enzyme is involved in the IL-5–stim-
ulated chemokinesis of bone marrow eosinophils using ra-
pamycin, a selective inhibitor of p70S6K. Rapamycin (20
nM) did not significantly affect IL-5–stimulated chemoki-
nesis of guinea pig bone marrow eosinophils when tested in
the Transwell assay (Fig. 7 a).
The Effect of Wortmannin and Rapamycin on IL-5–stimulated
Release of Eosinophils from the Perfused Femoral Bone Marrow.
Using the in situ hind limb perfusion system, we examined
if wortmannin or rapamycin could inhibit IL-5–stimulated
mobilization of femoral marrow eosinophils. Wortmannin
(100 nM), rapamycin (100 nM), or vehicle (PBS/0.1%
BSA) were infused into the hind limb for 40 min and then
IL-5 (3 nM) or vehicle (PBS/0.1% BSA) was infused into
the hind limb for 10 min (10-min infusion indicated by the
solid bar in Fig. 7 b). The perfusion was continued for an
additional 50 min, with wortmannin, rapamycin, or vehicle
being infused for the duration of the perfusion. The leuko-
cytes released were collected in 10-min fractions, and
stained with Kimura’s stain for positive identification of
eosinophils. Wortmannin (100 nM) had no effect on the
basal release of noneosinophilic leukocytes (data not shown)
or basal (PBS) release of eosinophils from the femoral mar-
row (Fig. 7 b). However, wortmannin (100 nM) signifi-
cantly reduced the rate of IL-5–stimulated eosinophil re-
lease from the femoral marrow (Fig. 7 b). The total number
of eosinophils mobilized in response to IL-5 was inhibited
by 50% in the presence of wortmannin (100 nM) (IL-5 plus
vehicle released 7.6 6 1.3 3 105 eosinophils; IL-5 plus
wortmannin released 3.8 6 0.7 3 105 eosinophils; P ,
0.05). Rapamycin (100 nM) did not affect the rate of IL-5–
stimulated release of eosinophils from the femoral marrow
when tested in the hind limb perfusion system (Fig. 7 c).
These results suggest that IL-5–stimulated mobilization of
bone marrow eosinophils involves signaling through PI
3-kinase.
Table 1. IL-5–stimulated Chemokinesis of Guinea Pig Bone Marrow Eosinophils
Upper chamber IL-5
0 0.03 0.1 0.3 1
nM
0 1 3.74(0.41) 7.34(0.32) 9.28(0.77) 8.98(0.64)
Lower chamber IL-5 (nM)
0.03 2.38(0.09) 5.28(0.09) 7.82(0.89) 8.45(0.97) 7.38(0.76)
0.1 5.83(0.13) 6.90(0.69) 7.74(0.41) 8.17(0.73) 7.89(0.96)
0.3 6.18(0.45) 6.89(0.05) 9.09(0.43) 8.34(0.89) 7.59(0.59)
1 8.91(0.40) 8.37(0.41) 8.78(0.59) 9.11(0.75) 8.33(0.64)
Chemokinesis was demonstrated using checkerboard analysis of IL-5–stimulated eosinophil migration in the Transwell assay. A single cell suspen-
sion of 3 3 106 bone marrow leukocytes was placed in the upper chamber. IL-5 (0.03–1 nM) was placed in the upper and lower chambers in a
checkerboard pattern. After 90 min, eosinophils accumulated in the lower chamber were identified by flow cytometry. Migration of eosinophils is
expressed as the chemotactic index, mean 6 SEM, representative experiment done in triplicate.
Discussion
Mobilization of eosinophils is an important early step in
their trafficking to the lungs during allergic inflammatory
reactions. We have previously shown that IL-5, generated
during allergic inflammatory reactions, acts systemically to
release eosinophils selectively from the bone marrow (25).
In this paper we have investigated the mechanisms under-
lying the acute mobilization of eosinophils from the bone
marrow stimulated by IL-5. Examination of the process
histologically by light and electron microscopy revealed
that IL-5 stimulates a rapid movement of eosinophils from
the bone marrow hematopoietic compartment into the si-
nuses. Our data suggest that transmigration across the bone
marrow endothelium is a transcellular and not an intercel-
lular event, as has been demonstrated for other leukocytes
by serial thin sectioning (36–38) and has also recently been
reported for the migration of eosinophils and neutrophils
during their recruitment into inflammatory sites (39).
Using an in situ perfusion system of the guinea pig hind
limb, we showed directly that infusion of IL-5 stimulates a
dose-dependent selective release of eosinophils from the
bone marrow. The release process is rapid and the kinetics
of release in this model were comparable to the release in
vivo after intravenous IL-5 injection (25). At the highest
concentration of IL-5 tested, there appeared to be a deple-
tion of the finite pool of mobilizable eosinophils from the
bone marrow. In vivo this pool may be expanded, i.e., after
sensitization with an allergen or due to infection with para-
sitic worms (40), thereby increasing the number of eosino-
phils available for rapid release.
Mature eosinophils are released in response to IL-5. Us-
ing this system, we have previously demonstrated that un-
der these conditions IL-5 does not stimulate the release of
colony-forming progenitor cells from the bone marrow
(28). The mobilization of mature eosinophils in preference
to immature eosinophils may reflect changes in eosinophils
during maturation. These may include an increased motil-
ity and responsiveness to IL-5, an increased deformability
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aiding migration through tight fitting pores, and changes in
the expression of adhesion molecules.
In this study, we show that there are changes in the ex-
pression of adhesion molecules on eosinophils as they are
mobilized from the bone marrow in response to IL-5, by
comparing eosinophils in bone marrow with those re-
leased. We found that levels of the a4 integrin were the
same in these two populations, but the eosinophils mobi-
lized by IL-5 had no detectable expression of L-selectin and
an increase in b2 integrin expression. It has previously been
shown that neutrophils shed L-selectin as they move from
the hematopoietic compartment into the venous sinusoids
of the bone marrow and it was postulated that this could
control the release of neutrophils from the marrow (41).
Our results are consistent with this theory; however, we
have no direct evidence that L-selectin shedding is neces-
sary for the egress of eosinophils from the bone marrow.
We report here that the expression of b2 integrins was
upregulated on eosinophils as they left the bone marrow in
response to IL-5. Furthermore, a blocking Ab to the b2 in-
tegrin significantly inhibited the IL-5–stimulated mobiliza-
tion of eosinophils from the bone marrow. In vitro studies
have previously demonstrated that IL-5 stimulates b2 inte-
grin–mediated adhesion of eosinophils to human umbilical
vein endothelial cells (42) and in vivo the migration of eosin-
ophils from the blood into tissues has been shown to be de-
pendent on b2 integrins (43). It is possible that b2 integrins
may be necessary for migration of the eosinophils within the
hematopoietic compartment or their adhesion to and trans-
migration through the bone marrow endothelium.
In contrast to the effect of the blocking Ab to the b2 in-
tegrin, the blocking Ab to the a4 integrin significantly in-
creased the rate of eosinophil mobilization in response to
IL-5. This may be due to an inhibition of eosinophil adhe-
sion to the bone marrow sinus endothelium, as electron
micrographs show attachment of eosinophils to the luminal
surface of the endothelium after exposure to IL-5 using
the perfusion system. This is likely to be mediated by an at-
tachment of eosinophil very late antigen (VLA)4 to VCAM-1
expressed constitutively on the bone marrow endothelium
(32), before eosinophils leave the bone marrow in response
to IL-5. Consistent with this hypothesis was the finding
that a proportion of intravenously injected 111In-labeled
guinea pig peritoneal eosinophils (used as a surrogate for
newly migrated cells in vivo) localized in the bone marrow
by a VLA4-dependent mechanism. Furthermore, this hy-
pothesis can explain the report that in vivo blocking of
VLA4 or VCAM-1, but not intercellular adhesion molecule
(ICAM)-1, increases the blood eosinophil counts after al-
lergen challenge of sensitized mice, although having no ef-
fect on blood eosinophil levels of unchallenged sensitized
mice (44).
Our results show that the migration of eosinophils out of
the bone marrow involves adhesive interactions with the
a4 and b2 integrins. This may occur at several stages that re-
main to be identified, e.g., the adhesive interactions occur-
ring between the abluminal surface of the endothelium and
the leukocyte preparing to egress have not been defined
and warrant further investigation.
The results of the light and electron microscopy provide
evidence that eosinophil migration is a fundamental step in
the mobilization process. Using an in vitro assay system we
demonstrated that IL-5 is chemokinetic for guinea pig
bone marrow eosinophils. This finding is consistent with
previous studies that have shown that IL-5 is chemokinetic
for human peripheral blood eosinophils (45). Chemokinesis
is distinct from chemotaxis as it does not require a positive
gradient of the chemoattractant and the resulting cell
movement is random rather than directional. Our results
suggest that stimulating the random migration of eosino-
phils within the hematopoietic tissue is sufficient to pro-
mote the egress of eosinophils. This may be due to the cy-
Figure 7. Effect of the PI 3-kinase inhibitors wortmannin and
LY294002 on IL-5–stimulated eosinophil chemokinesis and mobilization
from the femoral bone marrow. (A) Guinea pig femoral bone marrow
leukocytes were incubated with wortmannin (1–50 nM), LY294002 (1–20
mM), or rapamycin (20 nM) for 30 min at 378C before being placed in
the upper Transwell chamber in the presence of IL-5 (3 nM). After incu-
bation at 378C for 1 h, eosinophils that accumulated in the lower Trans-
well chamber were quantified by flow cytometry. Eosinophil accumula-
tion is expressed as the chemotactic index, with accumulation in response
to vehicle having a chemotactic index of 1. Mean 6 SEM (triplicate val-
ues of a representative experiment). *P , 0.05, **P , 0.01.(B and C) Ki-
netics of IL-5–stimulated eosinophil mobilization from the perfused hind
limb in the presence of wortmannin (B) or rapamycin (C). The hind limb
was infused with wortmannin (100 nM), rapamycin (100 nM), or vehicle
(0.1% DMSO) for 40 min before infusion with IL-5 (3 nM, 10-min
pulse, black bar) or vehicle. Data expressed as the number of eosinophils
per milliliter of perfusate in each 10-min fraction, mean 6 SEM (n 5 4
separate perfusions).
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toarchitecture of the bone marrow where the hemopoietic
islands are surrounded by branching venous sinusoids (46).
We have previously demonstrated that eotaxin, a potent
eosinophil CC-chemokine, is chemotactic for bone mar-
row eosinophils and can stimulate the mobilization of eosin-
ophils from the bone marrow (28). Eotaxin has to establish
a positive gradient across the sinus endothelium, by means
of an elevated plasma concentration, to effect eosinophil
release. In contrast, IL-5, because of its chemokinetic activ-
ity, will be effective when present in plasma or if generated
extravascularly in the marrow. We found that IL-5 could
act synergistically together with eotaxin in this mobilization
process. Therefore, we hypothesize that a combination of
both chemokinesis and chemotaxis may be the most effec-
tive means of mobilizing eosinophils from the bone mar-
row (28).
Despite the apparent similarity between mechanisms of
eosinophil migration through the bone marrow sinus endo-
thelium effecting release and migration through micro-
vascular endothelial cells effecting recruitment to inflamma-
tory sites, there is an interesting difference. In our studies
both IL-5 and eotaxin can induce bone marrow eosinophil
release, i.e., both chemokinesis and chemotaxis are effective.
In contrast eotaxin, but not IL-5 is potent in stimulating re-
cruitment at sites of inflammation (25), i.e., chemotaxis but
not chemokinesis, is effective in this respect. This may be
generally applicable to other leukocyte types.
IL-5 binds to and activates specific tyrosine kinase–
linked IL-5 receptors expressed by eosinophils. A number
of signal transduction molecules are activated in response to
IL-5, including JAK1, JAK2, STAT1, Lyn, ERK2, and PI
3-kinase(47–49). In other cell types it has been demon-
strated that PI 3-kinase plays a central role in regulating cy-
toskeletal changes and cell migration (50–52). In this study,
we have demonstrated that the chemokinetic response of
IL-5–stimulated bone marrow eosinophils was inhibited by
wortmannin and LY294002, two selective inhibitors of PI
3-kinase. Furthermore, wortmannin (100 nM) markedly
inhibited the IL-5–stimulated mobilization of eosinophils
from the bone marrow. There are several potential molec-
ular downstream targets of PI 3-kinase that have been iden-
tified in other cellular systems. These include protein ki-
nase B, the rapamycin-sensitive p70S6K, and the focal
adhesion–associated proteins p125 focal adhesion kinase
and paxillin (53–56). It has been reported previously that
rapamycin partially inhibits IL-5–mediated eosinophil sur-
vival (57). However, in our study, rapamycin had no effect
on IL-5–stimulated eosinophil chemokinesis in vitro or in
the in situ perfusion system. Thus p70S6K does not appear
to be a downstream target of PI 3-kinase in this pathway.
The results of this study demonstrate that the emigration
of eosinophils from the bone marrow is a multistep process.
These steps may include release of mature eosinophils at-
tached to bone marrow stromal cells and extracellular ma-
trix, migration across the sinus endothelium, and release
from the luminal surface of the endothelium. We have
shown that adhesive interactions are important in regulat-
ing this process, a4 and b2 integrins acting in opposite di-
rections. The identical effects of the reagents tested here on
bone marrow eosinophil release and on eosinophil migra-
tion through an inert membrane in vitro reinforce the idea
that it is chemokinesis of the eosinophil that is the primary
response driving eosinophil mobilization in response to
IL-5. The overriding conclusion from these studies is that
eosinophil migration through the bone marrow sinus en-
dothelium is the pivotal mechanism regulating release and
as a consequence, this is an essential determinant of blood
and tissue eosinophilia.
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